Pharma News
FDA Approves Pair of Interchangeable Denosumab Biosimilars
The biosimilars Wyost and Jubbonti (denosumab-bddz) were approved as interchangeable products for Prolia and Xgeva for the treatment of osteoporosis, hypercalcemia, and to prevent skeletal-related events associated with bone metastases from solid tumors.
Source link
#FDA #Approves #Pair #Interchangeable #Denosumab #Biosimilars